Co. Inc. (NYSE:MRK), reducing the pharmaceutical giant's price target from $105.00 to $96.00, while keeping a Market Perform rating on the stock. Analysts at BMO Capital cited a decrease in confidence stemming from recent shifts in expectations for Merck's vaccine,

BMO Capital Markets has recently initiated Aflac Inc (AFL) stock to Market Perform rating, as announced on January 23, 2025, according to Finviz. Earlier, on October 9, 2024, TD Cowen had initiated the stock to Hold,

BMO Capital lowered the firm’s price target on Ingredion (INGR) to $133 from $147 and keeps a Market Perform rating on the shares after its Q4

BMO Capital Markets adjusted its outlook on DXC Technology (NYSE: NYSE:DXC) by increasing the price target from $25.00 to $26.00. The firm retained its Market Perform rating on the company's shares. The adjustment followed DXC Technology's recent earnings report,